Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.35 |
| ▸ | TERT | O14746 | 7/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868812 | 0.98 | HPGD (0.42) | HPGDALOX15SLC18A3APOBEC3AAPOBEC3G | |
| Hydrochloric Acid SCHEMBL7338246 | 0.95 | HPGD (0.41) | HPGDALOX15SLC18A3APOBEC3AAPOBEC3G | |
| Water SCHEMBL1358129 | 0.95 | HPGD (0.41) | HPGDALOX15SLC18A3APOBEC3AAPOBEC3G | |
| SCHEMBL10390898 | 0.91 | HPGD (0.39) | HPGDALOX15SLC18A3APOBEC3AAPOBEC3G | |
| Bromide SCHEMBL830312 | 0.86 | HPGD (0.46) | HPGDALOX15APOBEC3AAPOBEC3GCDC25A | |
| SCHEMBL14790594 | 0.84 | — | — | |
| SCHEMBL13197525 | 0.84 | HPGD (0.47) | HPGDALOX15APOBEC3AAPOBEC3GCDC25A | |
| Hydrochloric Acid SCHEMBL3653366 | 0.82 | HPGD (0.46) | HPGDALOX15APOBEC3AAPOBEC3GCDC25A | |
| SCHEMBL9935792 | 0.82 | HPGD (0.47) | HPGDALOX15APOBEC3AAPOBEC3GCDC25A | |
| Bromide SCHEMBL10860878 | 0.80 | HPGD (0.52) | HPGDALOX15APOBEC3AAPOBEC3GCDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089414-B1 | USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION | MERCK PATENT GMBH (DE) | 2013-03-06 | — | — | EP | claimed |
| US-8143381-B2 | Use of ionic liquids for membrane protein extraction | MERCK PATENT GMBH (DE) | 2012-03-27 | — | — | US | claimed |
| US-20100029917-A1 | USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION | MERCK PATENT GMBH (DE) | 2010-02-04 | — | — | US | claimed |
| EP-2089414-A1 | USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION | Merck Patent GmbH (DE) | 2009-08-19 | — | — | EP | claimed |
| WO-2008058604-A1 | USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | WO | claimed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | claimed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | claimed |
| CN-120097937-A | Synthesis method of N- (2-hydroxyethyl) -N-methylmorpholinium bromide | 中国科学院大连化学物理研究所 | 2025-06-06 | — | — | CN | disclosed |
| CN-120097937-A | Synthesis method of N- (2-hydroxyethyl) -N-methylmorpholinium bromide | 中国科学院大连化学物理研究所 | 2025-06-06 | — | — | CN | disclosed |
| EP-2089414-B1 | USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION | MERCK PATENT GMBH (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-8143381-B2 | Use of ionic liquids for membrane protein extraction | MERCK PATENT GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8097752-B2 | Antiprotozoal ring-substituted phospholipids | MAKSCIENTIFIC, LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20100029917-A1 | USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION | MERCK PATENT GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-1578754-A4 | ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS | MAKSCIENTIFIC LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20060105998-A1 | Antiprotozoal ring-substiuted phospholipids | MAK SCIENTIFIC CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1578754-A2 | ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS | MakScientific Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004041167-A2 | ANTIPROTOZOAL RING-SUBSTITUTED PHOSPHOLIPIDS | CALOGEROPOULOU THEODORA (GR) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105998-A1 | Antiprotozoal ring-substiuted phospholipids | PHOSPHO1, PLTP, PLA2G2C | HPGD 1742/4885ALOX15 571/4885SLC18A3 4229/4885 |
| US-20100029917-A1 | USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION | APMAP, VAMP8, VAMP7 | HPGD 4350/4885ALOX15 4529/4885SLC18A3 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.